Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine therapy in multiple sclerosis: an open label pilot study

V Bissay1, N De Klippel, L Herroelen

  • 1Department of Neurology, Academisch Ziekenhuis Vrije, Universiteit Brussel, Belgium.

Clinical Neuropharmacology
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and characterization of a new ensemble of cometary organic molecules.

Nature communications·2022
Same author

Perceived neuropsychological impairment inversely related to self-reported health and employment in multiple sclerosis.

European journal of neurology·2019
Same author

On the origin of molecular oxygen in cometary comae.

Nature communications·2018
Same author

European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke.

European journal of neurology·2017
Same author

Xenon isotopes in 67P/Churyumov-Gerasimenko show that comets contributed to Earth's atmosphere.

Science (New York, N.Y.)·2017
Same author

D<sub>2</sub>O and HDS in the coma of 67P/Churyumov-Gerasimenko.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2017
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Bromocriptine did not fully halt disease progression in multiple sclerosis (MS) patients. The pilot study showed most participants experienced worsening symptoms and new lesions despite treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Experimental allergic encephalitis serves as an animal model for multiple sclerosis (MS).
  • Bromocriptine has demonstrated potential in suppressing allergic encephalitis symptoms.

Purpose of the Study:

  • To evaluate the efficacy of bromocriptine in managing clinical and subclinical disease activity in patients with definite multiple sclerosis.

Main Methods:

  • An open pilot study involving 18 patients with definite MS (10 relapsing-remitting, 8 chronic progressive).
  • Patients received 2.5 mg of bromocriptine twice daily for 1 year.
  • Disease progression was monitored using EDSS scores, clinical relapses, MRI, and evoked potential tests.

Main Results:

Related Experiment Videos

  • After 1 year, 14 of 15 completers showed disease progression.
  • Progression indicators included worsening EDSS scores, clinical relapses, new MRI lesions, and altered evoked responses.
  • Bromocriptine did not completely suppress ongoing disease activity.

Conclusions:

  • Bromocriptine monotherapy does not appear to be a sufficient treatment to halt disease progression in multiple sclerosis patients.
  • Further research is needed to explore combination therapies or alternative treatments for MS.